From Lab to Production: The Five Critical Challenges of Biotech Scale-up

The science is often excellent. But scaling a biological process, defending a business case under investor conditions, holding your own against commodity producers and building market trust at the same time: these are the real challenges. Technical excellence alone is not enough. Business, process and market have to align simultaneously.

Business-Case Stability Under Investor Pressure

Investor decks built on optimistic yield assumptions from laboratory scale look convincing in the financing round and become a liability during scale-up. Process parameters that are stable in 2-litre fermenters behave fundamentally differently at cubic-metre scale: oxygen transfer, shear forces, temperature gradients. When titre projections from the lab protocol cannot be reproduced on pilot plants, a gap opens up between the communicated roadmap and operational reality - precisely the point at which investor confidence erodes.

The underlying problem is the separation of R&D and the financial model. When both sides operate with different yield assumptions and CAPEX calculations, strategic decisions are made on the basis of unreconciled data.

Process Transfer and Scaling Risks

The scale-up leap is not linear. Physical phenomena that are negligible at laboratory scale become dominant process variables at pilot scale. kLa values that are easy to achieve in a small bioreactor require considerably more effort during scale-up - dissolved-oxygen gradients impair productivity. Agitation that is necessary for good mixing can exceed the shear-force tolerance of sensitive organisms.

On top of this comes the comparability question under ICH Q5E: anyone who plans the demonstration that the scaled-up material is comparable to the clinical reference material only after the scale-up leap risks the new material being classified as a different product in regulatory terms, so that the clinical data base no longer holds. The comparability demonstration must be part of the scale-up strategy, not a follow-up to it.

Competition Against Established Producers

Bio-based products often enter markets already occupied by large industrial groups or petrochemical alternatives with decades of process optimisation. Established manufacturers have amortised equipment, optimised processes and existing customer relationships. Start-ups begin without these advantages.

For many bio-based molecules, the price of the petrochemical equivalent sets the price ceiling. If the oil price falls, the economic advantage of bio-based products weakens, regardless of process efficiency. When the gross margin is under pressure from the outset, the path to cash-flow profitability lengthens - which makes future financing rounds harder under less favourable conditions.

Raw-Material Dependencies

Biological production processes rely on agricultural raw materials whose price, availability and quality can fluctuate considerably. Commodity agricultural markets respond to weather events, trade policy and competing uses. Biotech start-ups often lack the purchasing power to secure long-term supply contracts on favourable terms.

For processes based on agricultural by-products, variability in the composition of the substrate translates directly into process variability and yield uncertainty. Raw-material risk is not an external factor but an integral part of process design.

Building Market Trust

A technically superior bio-based product that lacks market acceptance generates no revenue. Sustainability claims are scrutinised with increasing effort. Procurement teams at large industrial companies demand validated performance data before they consider switching from conventional alternatives.

The scale-trust paradox is the fundamental problem: customers demand assurance of stable supply capability in production quantities before they commit. But scale requires customers. This chicken-and-egg problem cannot be solved through persuasion, but through a validation strategy that builds the commercial track record step by step: pilot programmes, technical qualification at the customer's site, regulatory positioning - before the main contract is signed.

---

The five challenge clusters are not sequential but occur simultaneously. A solution that is convincing on the technical side but neglects market trust comes to a standstill just as early as one that stabilises the business case but underestimates the process transfer. Scale-up succeeds when all dimensions are addressed in an integrated way.